A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Trial Profile

A Multicenter, Single-Arm, Open-Label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Acronyms STRATUS
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 11 Feb 2017 This trial was completed in Poland, according to the European Clinical Trials Database record.
    • 07 Jun 2016 Pooled analysis results from this trial and other two trial (NCT00833833, NCT01311687) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top